{"schema":"hottub-news/story/v1","story":"st_zzezcrelyqsr2h4u4atq","title":"Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026","title_en":null,"outlets":4,"brief":null,"page":"https://hottub.news/stories/candel-therapeutics-announces-new-data-showing-sustained-immune-zzezcrelyq","count":4,"items":[{"id":"n_gez67ljibatzmsk5a7rq","seq":1368421,"kind":"article","title":"Aglatimagene Besadenovec Shows Durable Immune Activity in Intermediate-Risk Localized Prostate Cancer","url":"https://www.onclive.com/view/aglatimagene-besadenovec-shows-durable-immune-activity-in-intermediate-risk-localized-prostate-cancer","published":"2026-10-02T12:00:00Z","seen":"2026-10-02T14:47:20Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"story":"st_zzezcrelyqsr2h4u4atq","category":"health","category_p":0.44999998807907104,"sentiment":"neutral","tone":-0.30000001192092896,"political":0.05999999865889549},{"id":"n_rzwgj7c25bv5ba5wrqqq","seq":901290,"kind":"press_release","title":"Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer","url":"https://www.globenewswire.com/news-release/2026/09/30/3371862/0/en/candel-therapeutics-announces-integrated-clinical-and-biomarker-data-that-showed-durable-local-and-systemic-immune-activation-after-aglatimagene-besadenovec-in-intermediate-risk-lo.html","summary":"NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial ( NCT07332000 ) in patients with intermediate-risk localized prostate cancer. These data, together with histologic and clinical…","published":"2026-09-30T12:30:00Z","seen":"2026-09-30T12:37:48Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"},{"id":"Q181257","name":"prostate cancer","type":"other"}],"story":"st_zzezcrelyqsr2h4u4atq","category":"health","category_p":0.6399999856948853,"sentiment":"neutral","tone":0.15000000596046448,"political":0.05000000074505806},{"id":"n_e23kjzswqon7fb2rma2q","seq":907694,"kind":"article","title":"Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026","url":"https://www.manilatimes.net/2026/09/30/tmt-newswire/globenewswire/candel-therapeutics-announces-new-data-showing-sustained-immune-remodeling-more-than-two-years-after-aglatimagene-besadenovec-treatment-in-localized-prostate-cancer-at-astro-2026/2436061","published":"2026-09-30T12:19:00Z","seen":"2026-09-30T12:52:37Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business","science"],"story":"st_zzezcrelyqsr2h4u4atq","category":"health","category_p":0.6000000238418579,"sentiment":"positive","tone":-0.23999999463558197,"political":0.03999999910593033},{"id":"n_zzezcrelyqsr2h4u4atq","seq":897533,"kind":"press_release","title":"Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026","url":"https://www.globenewswire.com/news-release/2026/09/30/3371847/0/en/candel-therapeutics-announces-new-data-showing-sustained-immune-remodeling-more-than-two-years-after-aglatimagene-besadenovec-treatment-in-localized-prostate-cancer-at-astro-2026.html","summary":"NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the…","published":"2026-09-30T12:05:00Z","seen":"2026-09-30T12:13:15Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"}],"mentions":2,"story":"st_zzezcrelyqsr2h4u4atq","category":"health","category_p":0.6000000238418579,"sentiment":"positive","tone":0.30000001192092896,"political":0.03999999910593033}]}